Form DEFA14A BridgeBio Pharma, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
April 28, 2026 2:00 PM EDTRaymond James analyst Martin Auster reiterated an Outperform rating and $89.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Today, Pfizer announced (here) that the company has entered into settlement agreements with several generic drug manufacturers over patent infringement lawsuits relating to Pfizers blockbuster ATTR-CM product, Vyndamax (tafamidis). Here, we summarize key takeaways and contextualize readthrough to BridgeBios lead ATTR-CM asset, Attruby. Vyndamax settlements and June 2031 LoE timeline roughly within Street expectations. Todays settlements extend the effective U.S. patent expiry for Vyndamax to June 1, 2031 (pending other... More
TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'
April 28, 2026 11:46 AM EDTTD Cowen analyst Tyler Van Buren reiterated a Buy rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "The PFE taf settlement date of June 2031 (w/ potential for 6 mos of exclusivity) gives BBIO 7.5-8 years to launch... More
Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'
April 28, 2026 11:25 AM EDTMizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Pfizer (PFE, NC) just announced that the recent settlements with Dexcel, Cipla and Hikma (all NC) extended Vyndamax's LOE to 6/1/2031 (from YE2028).... More
Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term'
April 28, 2026 9:48 AM EDTMizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "We've just learned that Hikma/PFE (both NC) settled in their current litigation of case 1:23-cv-00879 (Document 334), which follows both recent... More
